Combination immunotherapy and antifungal chemotherapy

Clinical Infectious Diseases

Volumn 26, Issue 6, 1998, Pages 1266-1269

  Stevens, David A ^a  

^a SANTA CLARA VALLEY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; FLUCONAZOLE; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; ITRACONAZOLE; RECOMBINANT COLONY STIMULATING FACTOR 1; RECOMBINANT CYTOKINE; RECOMBINANT GAMMA INTERFERON; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR;

ADJUVANT CHEMOTHERAPY; COMBINATION CHEMOTHERAPY; CYTOKINE PRODUCTION; DRUG POTENTIATION; EFFECTOR CELL; HELPER CELL; HOST RESISTANCE; HUMAN; IMMUNOTHERAPY; MYCOSIS; NONHUMAN; PRIORITY JOURNAL; REVIEW;

EID: 0031810757     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/516362     Document Type: Review

References (22)

1. Stevens DA, the Coccidioidomycosis Cooperative Treatment Group. Transfer factor therapy of infectious diseases. In: Frost EC, Gomez N, Zaias N, eds. Advances in dermatopharmacology. New York: Spectrum Publications, 1977:67-74.
2. Stevens DA, Brummer E. Cytokines and the host-fungal interplay. In: Vanden Bossche H, Odds FC, Stevens DA, eds. The host-fungus interplay. Bethesda, Maryland: National Foundation for Infectious Diseases, 1997:135-9.
3. Dromer F, Charriere J, Contrepois A, Carbon C, Yeni P. Protection of mice against experimental cryptococcosis by anti-Cryptococcus neoformans monoclonal antibody. Infect Immun 1987:55:749-52.
4. Feldmesser M, Mukherjee J, Casadevall A. Combination of flucytosine and capsule binding monoclonal antibody in therapy of murine Crypto-coccus neoformans infections and in vitro. J Antimicrob Chemother 1996;37:617-22.
5. Stevens DA. Interferon-gamma and fungal infections. In: Jaffe HS, Bucalo LR, Sherwin SA, eds. The anti-infective applications of interferon-gamma. New York: Marcel Dekker, 1992:279-91.
6. Brummer E, Hanson LH, Stevens DA. IL-4, IgE, and gamma-interferon production in pulmonary blastomycosis: comparison in mice untreated, immunized, or treated with an antifungal (SCH 39304). Cell Immunol 1993;149:258-67.
7. Hosteller JS, Drummer E, Coffman RL, Stevens DA. Efficacy of anti-IL-4, interferon-gamma, and an antifungal triazole (SCH 42427) in chronic paracoccidioidomycosis: IgE levels correlated with outcome. Clin Exp Immunol 1993;9:11-6.
8. Bistoni F, Mencacci A, Cenci E, et al. Physiopathological role of cytokines induced by Candida: rational basis for immunotherapy. In: Vanden Bossche H, Odds FC, Stevens DA, eds. The host-fungus interplay. Bethesda, Maryland: National Foundation for Infectious Diseases. 1997: 141-8.
9. Joly V, Saint-Julien L, Carbon C, Yeni P. In vivo activity of interferonγ in combination with amphotericin B in the treatment of experimental cryptococcosis. J Infect Dis 1994;170:1331-4.
10. Lutz JE, demons KV, Stevens DA. Synergy between interferon-gamma and antifungal chemotherapy in systemic cryptococcosis. Clin Infect Dis 1996;23:899.
11. Brunda MJ. Interleukin-12. J Leukocyte Biol 1994;55:280-8.
12. Clemons KV, Brummer E, Stevens DA. Cytokine treatment in central nervous system infection: efficacy of interleukin-12 alone and synergy with conventional antifungal therapy in experimental cryptococcosis. Antimicrob Agents Chemother 1994;38:460-4.
13. Brummer E, Stevens DA. Synergy of azoles with macrophages in killing fungi. In: Vanden Bossche H, Odds FC, Stevens DA, eds. The hostfungus interplay. Bethesda, Maryland: National Foundation for Infectious Diseases, 1997:317-27.
14. Van't Wout JW, Meynaar I, Linde I, Poell R, Mattie H, Van Furth R. Effect of amphotericin B, fluconazole and itraconazole on intracellular Candida albicans and germ tube development in macrophages. J Antimicrob Chemother 1990;25:803-11.
15. Roilides E, Walsh TJ, Rubin M, Venzon D, Pizzo PA. Effects of antifungal drugs on the function of human neutrophils in vitro. Antimicrob Agents Chemother 1990;34:196-201.
16. Nassar F, Brummer E, Stevens DA. Different components in human serum inhibit multiplication of Cryptococciis neoformans and enhance fluconazole activity. Antimicrob Agents Chemother 1995;39:2490-3.
17. Brummer E, Natarajan U, Randhawa N, Stevens DA. G-CSF and GM-CSF activation of phagocytes for enhanced candidacidal activity and synergy with fluconazole. J Allergy Clin Immunol 1997;99:S14.
18. Rowe JM, Anderson JW, Mazza JJ, et al. Randomized placebo-controlled phase III study of granulocyte-macrophage-colony stimulating factor in adult patients (>55 to 70 years of age) with acute myelogenous leukemia: a study by the Eastern Cooperative Oncology Group (E1490). Blood 1995:86:457-62.
19. Yamamoto Y, Uchida K, Klein TW, Friedman H, Yamaguchi H. Immunomodulators and fungal infections: use of antifungal drugs in combination with G-CSF. In: Friedman H, Klein TW, Yamaguchi H, eds. Microbial infections. New York: Plenum Press, 1992:231-41.
20. Polak-Wyss A. Protective effect of human granulocyte-colony-stimulating factor on Cryplococcus and Aspergillus infections in normal and immunosuppressed mice. Mycoses 1991;34:205-15.
21. Wolf JE, Massof SE. In vivo activation of macrophage oxidative burst activity by cytokines and amphotericin B. Infect Immun 1990;5:1296300.
22. Bogle RG, Whitley GSJ, Soo S-C, Johnstone AP, Vallance P. Effect of antifungal imidazoles on mRNA levels and enzyme activity of inducible nitric oxide synthase. Br J Pharmacol 1994;111:1257-61.